The Third Yellow River Urology Congress and the 31st Academic Conference of the Shandong Medical Association on Urology were recently held successfully. The conference brought together numerous experts and scholars in urology from across China to discuss cutting-edge advances, innovations in clinical practice, talent development, and regional collaboration. Oncology Frontier · UroStream invited Professor Liqun Zhou of Peking University First Hospital to provide an in-depth analysis of how to advance high-quality clinical research in urology and support the professional development of young physicians.

In recent years, the incidence and mortality of prostate cancer in China have increased significantly, driven by socioeconomic development and population aging, resulting in a growing disease burden. Androgen deprivation therapy (ADT), whether used alone or in combination, remains a cornerstone of comprehensive prostate cancer management. With updates to the Chinese Expert Consensus on Testosterone Management in Prostate Cancer and the Expert Consensus on Comprehensive Management of Prostate Cancer, clinical recommendations have evolved beyond achieving castration-level testosterone (<50 ng/dL) toward deep testosterone suppression (<20 ng/dL) and rapid, sustained PSA control, which may provide patients with better outcomes. Against this background, Oncology Frontier invited Professor Shaoxing Zhu of Fujian Medical University Union Hospital to discuss the evidence supporting deep testosterone suppression, individualized perioperative treatment strategies, and approaches that balance treatment efficacy with quality of life, with the goal of further improving survival and quality of life among patients with prostate cancer in China.

In recent years, technologies, therapeutic agents, and treatment concepts in urologic oncology have continued to evolve, with precision, minimally invasive treatment, and functional preservation emerging as key directions for high-quality specialty development. From 5G-enabled remote robotic surgery expanding access to high-quality medical resources, to the continued advancement of systemic therapy for prostate cancer toward earlier stages of disease, and the development of surgical techniques centered on urinary continence and sexual function preservation, urologic oncology is gradually moving beyond a sole focus on tumor control toward comprehensive management that balances long-term survival with quality of life. In this issue, Oncology Frontier · UroStream invited Professor Shangqing Ren of Sichuan Provincial People's Hospital to share insights into important advances in urologic oncology, functional preservation in prostate cancer and related technical approaches, as well as the clinical and research development pathways for young urologists, providing practical experience and perspectives on innovation in urologic care and the development of the next generation of specialists.

High-risk and locally advanced prostate cancer is characterized by substantial biological heterogeneity, with significant differences in recurrence risk, metastatic potential, and treatment response among patients, making it a major challenge in clinical practice. With the development of novel androgen receptor pathway inhibitors, PSMA PET/CT, multi-omics technologies, and artificial intelligence, overcoming the limitations of traditional risk stratification, accurately identifying patients at truly extremely high risk, and integrating local and systemic therapies to improve long-term outcomes have become important areas of research. Oncology Frontier · UroStream invited Professor Mo Zhang of the Department of Urology, First Hospital of China Medical University, for an in-depth interview on the institution's single-center experience, precision stratification strategies, and future research directions in high-risk and locally advanced prostate cancer.

In recent years, the treatment paradigm for advanced prostate cancer has undergone a profound transformation, shifting from conventional empiric treatment toward precision stratification. With the increasing availability of genetic testing and the emergence of novel targeted therapies, individualized treatment based on molecular characteristics has become an important direction in clinical practice. Oncology Frontier · UroStream invited Professor Xiaojie Bian of Fudan University Shanghai Cancer Center for an in-depth interview on treatment decisions guided by genetic testing, individualized treatment strategies, and potential future breakthroughs.

For patients with kidney cancer who undergo radical surgery, reducing the risk of postoperative recurrence, prolonging disease-free survival, and ultimately improving overall survival have long remained key clinical priorities. In recent years, postoperative adjuvant therapy for kidney cancer has evolved from investigations of targeted therapies to breakthroughs with immunotherapy and, more recently, combinations of immunotherapy with novel targeted agents. However, because adjuvant therapy is administered to patients with no radiographically evident disease, accurately identifying microscopic residual disease, selecting patients most likely to benefit, and balancing efficacy against toxicity remain major challenges in clinical practice. Oncology Frontier · UroStream invited Professor Liangyou Gu of the Chinese PLA General Hospital for an in-depth interview to discuss major advances in postoperative adjuvant therapy for kidney cancer, strategies for identifying patients most likely to benefit, and future directions in the field.